FindMyKOL
Clinical trialNCT00498615CompletedPhase 3Interventional

A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon

NCT00498615 is a phase 3 interventional trial sponsored by Johns Hopkins University. As of 18 Nov 2026, it is completed. It studies Fasudil in Raynaud and Scleroderma. The registry lists an enrollment of 17 participants at 1 site in 1 country. The registry lists a start date of 30 Apr 2007 and a primary completion date of 31 Mar 2012.

SponsorJohns Hopkins University →Enrollment17RaynaudScleroderma
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00498615
FieldValue
Registry IDNCT00498615
StatusCompleted
PhasePhase 3
Study typeInterventional trial
Lead sponsorJohns Hopkins University
Enrollment17
Registered sites1
Countries1
ConditionsRaynaud and Scleroderma
DrugsFasudil
Start30 Apr 2007
Primary completion31 Mar 2012
Study completion31 Mar 2012
Last update posted4 Nov 2014

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Raynaud's phenomenon is thought to occur when, in response to cold or emotional stress, there is closure of the digital arteries and cutaneous arterioles leading to the clinical finding of sharp demarcated digital pallor and cyanosis of the distal skin of the fingers and/or toes. Patients often continue to experience problems despite current available treatment. The investigators' study will investigate the use of a new vasodilator called Fasudil, a Rho-kinase inhibitor. The investigators' hypothesis is that Fasudil will prevent vasoconstriction of digital and cutaneous arteries during a standard laboratory based cold exposure and will therefore improve digital blood flow and skin temperature recovery time following cold challenge. These data will provide the rationale for a more elaborate clinical trials in real life situations.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Maryland, United States1 site
  • Johns Hopkins University

    Baltimore

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMaryland: 1 siteMD1DelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Fasudil
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT00498615

Each answer restates registry values shown on this page.

What is NCT00498615?

NCT00498615 is a phase 3 interventional trial sponsored by Johns Hopkins University. It studies Fasudil in Raynaud and Scleroderma.

Who leads NCT00498615?

The registry names Fredrick M Wigley, M.D. (principal investigator, Johns Hopkins University) as the overall official.

Where does NCT00498615 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT00498615 study?

The registered drug and biological interventions are Fasudil.

When did NCT00498615 end?

The registry lists a primary completion date of 31 Mar 2012 and a study completion date of 31 Mar 2012. The sponsor last updated the record on 4 Nov 2014.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.